Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Official title: A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2024-05-10
Completion Date
2026-05
Last Updated
2024-06-14
Healthy Volunteers
No
Conditions
Interventions
ZG005 Powder for Injection
intravenous infusion(IV), once every 3 weeks
Donafenib Tosilate Tablets
The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Locations (1)
The Second Affiliated Hospital of Army Medical University
Chongqing, Chongqing Municipality, China